The clinical role of genetic polymorphisms in drug-metabolizing enzymes
- 5 June 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 8 (1), 4-15
- https://doi.org/10.1038/sj.tpj.6500462
Abstract
No abstract availableKeywords
This publication has 97 references indexed in Scilit:
- Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN‐38 glucuronidation in Japanese patients with cancerCancer Science, 2006
- TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?Trends in Pharmacological Sciences, 2006
- Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicineThe Pharmacogenomics Journal, 2006
- CYP2C19 Polymorphism and Proton Pump InhibitorsBasic & Clinical Pharmacology & Toxicology, 2004
- The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumonThrombosis and Haemostasis, 2004
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazoleBritish Journal of Clinical Pharmacology, 1998
- Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiencyTrends in Pharmacological Sciences, 1995
- Comparison of the pharmacokinetics of moclobemide in poor and efficient metabolizers of debrisoquineActa Psychiatrica Scandinavica, 1990
- Oxidation Phenotype — A Major Determinant of Metoprolol Metabolism and ResponseThe New England Journal of Medicine, 1982